Researchers screening blood donors in Argentina during a mosquito-borne virus outbreak found the virus in someone who felt completely fine. Among 637 donors living in outbreak-affected areas, one carried the Western equine encephalitis virus in their blood without any symptoms.
The finding was published in Emerging Infectious Diseases, the CDC's peer-reviewed journal. Genetic sequencing placed the donor's virus within the contemporary South American outbreak lineage, consistent with ongoing regional transmission rather than an unrelated source.
One donor out of 637 is a small number, and it should be read as a signal about system design rather than as an emergency. The authors wrote that the findings demonstrate "silent WEEV circulation among blood donors" and highlight the role of donor surveillance as a sentinel system for emerging arboviruses. That is the practical point for readers anywhere, including in the United States.
One Donor Out of 637 Tested
Western equine encephalitis virus reemerged in Argentina in 2023 after nearly three decades of quiet. Before that, the last confirmed human case in the country was in 1996. Argentine health authorities confirmed 107 human cases and 12 deaths during the outbreak. A separate regional analysis of the outbreak covering Argentina and Uruguay from November 2023 through April 2024 counted 217 human cases, 12 of them fatal, along with 2,548 equine cases, using a combination of laboratory and clinical epidemiologic criteria. The two counts differ because they cover different countries and apply different case definitions.
Argentine investigators responded by building interventions into a regional blood system run by the Fundación Banco Central de Sangre: real-time epidemiologic mapping of transmission locations, community-informed donor screening questions, reinforced reporting of symptoms after donation, and retrospective alphavirus-specific nucleic acid testing of plasma from donors in affected areas. That last step, which looks for viral genetic material rather than antibodies, is what identified the symptom-free donor.
The reason this matters is a basic feature of arbovirus biology. Most people infected with these viruses never develop symptoms. A donor who feels well and passes a health questionnaire can still be viremic, meaning the virus is present in their bloodstream. Screening questions cannot detect that. Only laboratory testing can.
AABB, the United States-based association that sets standards for blood banks, reviewed the manuscript through its Transfusion Transmitted Diseases Committee and described the observation as expected and consistent with reports from outbreaks of other arboviral agents, including West Nile virus, dengue, and St. Louis encephalitis. That framing is important. This is not a surprise finding. It confirms that a known vulnerability behaves as transfusion specialists predicted.
The U.S. Blood Screening System Was Built Around a Different Virus
American blood banks already screen donations for West Nile virus using nucleic acid testing, a practice adopted in 2003 after transfusion-transmitted infections were documented. Donors who test positive are deferred, and transfusion-transmitted West Nile virus has been rare since.
Western equine encephalitis virus is not part of routine screening in the United States. Neither are most other domestic arboviruses. The CDC's guidance on eastern equine encephalitis notes that while transmission of that virus through blood transfusion has not been documented, it is considered biologically plausible, and transmission through organ transplantation has been documented in one case in which a single donor infected three recipients. The agency instructs clinicians to immediately inform blood and tissue banks if a patient with a diagnosis donated blood, tissues, or organs within the four weeks before illness onset. That is a reactive safeguard, not a screening program.
The distinction matters because the two systems fail in different ways. Universal nucleic acid testing can catch a viremic donor before a unit is released. Notification after the fact depends on someone getting sick, being correctly diagnosed with a rare virus, and the donation being connected in time. The Argentine study is essentially a demonstration of what molecular testing finds that symptom-based systems cannot.
Distance from the Outbreak Does Not Mean Distance from the Question
There is no evidence of Western equine encephalitis virus circulating in United States blood donors, and no United States agency has proposed adding it to routine screening. Readers should not interpret this study as a reason to avoid a transfusion or to hesitate about donating blood. What was measured here is one detection among 637 donors during an active outbreak in another hemisphere.
The relevant connection runs through preparedness and cost. Adding a screening assay to the national blood supply is expensive, and blood centers already operate under financial pressure. The American Red Cross declared an emergency blood shortage in July after the national supply fell nearly 25 percent in June, with distributions to hospitals running about 3,500 units per week above expected levels. A system under that kind of strain has limited capacity to absorb new testing requirements quickly, which is an argument for deciding what would trigger a change before the trigger arrives rather than after.
Blood donor screening also produces public health information that clinical surveillance misses entirely. In California this year, Fresno County identified its first human West Nile case of 2026 through routine testing of a blood donor rather than through a patient seeking care, as MedicalDaily reported when three Central Valley counties confirmed initial cases. That is the sentinel function the Argentine authors described, operating domestically.
Several things remain genuinely unknown. Whether Western equine encephalitis virus will reach North America in a form that sustains human transmission remains unresolved. Whether a single symptom-free viremic donor represents a rare event or an underdetected pattern cannot be determined from 637 samples. And because no transfusion-transmitted case of this virus has been documented, the theoretical risk has not been quantified in practice.
For readers, the reasonable actions are ordinary. Eligible donors should continue giving, because the shortage is a concrete present harm and the screening question raised here is theoretical and geographically remote. Anyone who develops fever, severe headache, confusion, or neck stiffness within weeks of a transfusion should inform their clinician about the transfusion, as this is useful information regardless of the cause. Travelers to areas with active arbovirus transmission should use repellent and follow standard bite prevention.
Federal blood safety policy changes would come from the FDA, typically with input from groups such as AABB and the CDC, and no such action has been proposed. The more likely near-term development is the publication of expanded surveillance rather than new screening requirements.
Key Questions Answered
What did the study find? Among 637 blood donors in outbreak-affected areas of Argentina, one carried the Western equine encephalitis virus without symptoms. Sequencing linked the virus to the contemporary South American outbreak lineage.
Is the U.S. blood supply at risk? There is no evidence of this virus in United States donors, and no proposal to add it to screening. United States donations are already screened for West Nile virus using nucleic acid testing.
Has anyone caught this virus from a transfusion? No transfusion-transmitted case of Western equine encephalitis virus has been documented. The concern is biological plausibility, not observed transmission.
Why can't donor questionnaires catch this? Most arbovirus infections cause no symptoms. A donor can feel completely well while the virus is present in their blood. Only laboratory testing detects it.
Should I still donate blood? Yes. The Red Cross declared an emergency blood shortage in July after the national supply fell nearly 25 percent in June. The shortage is a present harm, and this screening question is theoretical.
What is nucleic acid testing? A laboratory method that directly detects viral genetic material rather than antibodies, allowing detection before the immune system responds.
What happens next? Continued surveillance publication is more likely than new screening requirements. Any change to United States blood safety would come from the FDA.
